Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Identifieur interne : 000032 ( Main/Exploration ); précédent : 000031; suivant : 000033Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Auteurs : Loukman Omarjee [France] ; Anne Janin [France] ; Frédérique Perrot [France] ; Bruno Laviolle [France] ; Olivier Meilhac [France] ; Guillaume Mahe [France]Source :
- Clinical immunology (Orlando, Fla.) [ 1521-7035 ] ; 2020.
Descripteurs français
- KwdFr :
- Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (immunologie), Betacoronavirus (pathogénicité), Cytokines (antagonistes et inhibiteurs), Cytokines (génétique), Cytokines (immunologie), Facteurs immunologiques (usage thérapeutique), Humains (MeSH), Immunité innée (effets des médicaments et des substances chimiques), Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Lymphocytes T (effets des médicaments et des substances chimiques), Lymphocytes T (immunologie), Lymphocytes T (virologie), Pandémies (MeSH), Pneumopathie virale (immunologie), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), Régulation de l'expression des gènes (MeSH), Sirolimus (usage thérapeutique), Thérapie moléculaire ciblée (méthodes), Évolution de la maladie (MeSH).
- MESH :
- antagonistes et inhibiteurs : Cytokines.
- effets des médicaments et des substances chimiques : Betacoronavirus, Immunité innée, Lymphocytes T.
- génétique : Cytokines.
- immunologie : Betacoronavirus, Cytokines, Infections à coronavirus, Lymphocytes T, Pneumopathie virale.
- méthodes : Thérapie moléculaire ciblée.
- pathogénicité : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Facteurs immunologiques, Sirolimus.
- virologie : Infections à coronavirus, Lymphocytes T, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Humains, Pandémies, Régulation de l'expression des gènes, Évolution de la maladie.
English descriptors
- KwdEn :
- Betacoronavirus (drug effects), Betacoronavirus (immunology), Betacoronavirus (pathogenicity), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (immunology), Coronavirus Infections (virology), Cytokine Release Syndrome (etiology), Cytokine Release Syndrome (immunology), Cytokine Release Syndrome (pathology), Cytokine Release Syndrome (prevention & control), Cytokines (antagonists & inhibitors), Cytokines (genetics), Cytokines (immunology), Disease Progression (MeSH), Gene Expression Regulation (MeSH), Humans (MeSH), Immunity, Innate (drug effects), Immunologic Factors (therapeutic use), Molecular Targeted Therapy (methods), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (immunology), Pneumonia, Viral (virology), Sirolimus (therapeutic use), T-Lymphocytes (drug effects), T-Lymphocytes (immunology), T-Lymphocytes (virology).
- MESH :
- chemical , antagonists & inhibitors : Cytokines.
- drug effects : Betacoronavirus, Immunity, Innate, T-Lymphocytes.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- etiology : Cytokine Release Syndrome.
- chemical , genetics : Cytokines.
- immunology : Betacoronavirus, Coronavirus Infections, Cytokine Release Syndrome, Cytokines, Pneumonia, Viral, T-Lymphocytes.
- methods : Molecular Targeted Therapy.
- pathogenicity : Betacoronavirus.
- pathology : Cytokine Release Syndrome.
- prevention & control : Cytokine Release Syndrome.
- chemical , therapeutic use : Immunologic Factors, Sirolimus.
- virology : Coronavirus Infections, Pneumonia, Viral, T-Lymphocytes.
- Disease Progression, Gene Expression Regulation, Humans, Pandemics.
DOI: 10.1016/j.clim.2020.108464
PubMed: 32405269
PubMed Central: PMC7217787
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.</title>
<author><name sortKey="Omarjee, Loukman" sort="Omarjee, Loukman" uniqKey="Omarjee L" first="Loukman" last="Omarjee">Loukman Omarjee</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France. Electronic address: loukman.omarjee@chu-rennes.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Janin, Anne" sort="Janin, Anne" uniqKey="Janin A" first="Anne" last="Janin">Anne Janin</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perrot, Frederique" sort="Perrot, Frederique" uniqKey="Perrot F" first="Frédérique" last="Perrot">Frédérique Perrot</name>
<affiliation wicri:level="3"><nlm:affiliation>Cellular and Molecular Biology Consultant, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Cellular and Molecular Biology Consultant, Rennes F-35033</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Laviolle, Bruno" sort="Laviolle, Bruno" uniqKey="Laviolle B" first="Bruno" last="Laviolle">Bruno Laviolle</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meilhac, Olivier" sort="Meilhac, Olivier" uniqKey="Meilhac O" first="Olivier" last="Meilhac">Olivier Meilhac</name>
<affiliation wicri:level="3"><nlm:affiliation>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448</wicri:regionArea>
<placeName><region type="region" nuts="2">La Réunion</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mahe, Guillaume" sort="Mahe, Guillaume" uniqKey="Mahe G" first="Guillaume" last="Mahe">Guillaume Mahe</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32405269</idno>
<idno type="pmid">32405269</idno>
<idno type="doi">10.1016/j.clim.2020.108464</idno>
<idno type="pmc">PMC7217787</idno>
<idno type="wicri:Area/Main/Corpus">000075</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000075</idno>
<idno type="wicri:Area/Main/Curation">000075</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000075</idno>
<idno type="wicri:Area/Main/Exploration">000075</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.</title>
<author><name sortKey="Omarjee, Loukman" sort="Omarjee, Loukman" uniqKey="Omarjee L" first="Loukman" last="Omarjee">Loukman Omarjee</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France. Electronic address: loukman.omarjee@chu-rennes.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Janin, Anne" sort="Janin, Anne" uniqKey="Janin A" first="Anne" last="Janin">Anne Janin</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perrot, Frederique" sort="Perrot, Frederique" uniqKey="Perrot F" first="Frédérique" last="Perrot">Frédérique Perrot</name>
<affiliation wicri:level="3"><nlm:affiliation>Cellular and Molecular Biology Consultant, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Cellular and Molecular Biology Consultant, Rennes F-35033</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Laviolle, Bruno" sort="Laviolle, Bruno" uniqKey="Laviolle B" first="Bruno" last="Laviolle">Bruno Laviolle</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meilhac, Olivier" sort="Meilhac, Olivier" uniqKey="Meilhac O" first="Olivier" last="Meilhac">Olivier Meilhac</name>
<affiliation wicri:level="3"><nlm:affiliation>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448</wicri:regionArea>
<placeName><region type="region" nuts="2">La Réunion</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mahe, Guillaume" sort="Mahe, Guillaume" uniqKey="Mahe G" first="Guillaume" last="Mahe">Guillaume Mahe</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical immunology (Orlando, Fla.)</title>
<idno type="eISSN">1521-7035</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (immunology)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Cytokine Release Syndrome (etiology)</term>
<term>Cytokine Release Syndrome (immunology)</term>
<term>Cytokine Release Syndrome (pathology)</term>
<term>Cytokine Release Syndrome (prevention & control)</term>
<term>Cytokines (antagonists & inhibitors)</term>
<term>Cytokines (genetics)</term>
<term>Cytokines (immunology)</term>
<term>Disease Progression (MeSH)</term>
<term>Gene Expression Regulation (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunity, Innate (drug effects)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Molecular Targeted Therapy (methods)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Sirolimus (therapeutic use)</term>
<term>T-Lymphocytes (drug effects)</term>
<term>T-Lymphocytes (immunology)</term>
<term>T-Lymphocytes (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (immunologie)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Cytokines (antagonistes et inhibiteurs)</term>
<term>Cytokines (génétique)</term>
<term>Cytokines (immunologie)</term>
<term>Facteurs immunologiques (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Immunité innée (effets des médicaments et des substances chimiques)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Lymphocytes T (effets des médicaments et des substances chimiques)</term>
<term>Lymphocytes T (immunologie)</term>
<term>Lymphocytes T (virologie)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Régulation de l'expression des gènes (MeSH)</term>
<term>Sirolimus (usage thérapeutique)</term>
<term>Thérapie moléculaire ciblée (méthodes)</term>
<term>Évolution de la maladie (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Immunity, Innate</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
<term>Immunité innée</term>
<term>Lymphocytes T</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cytokine Release Syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term>
<term>Cytokines</term>
<term>Infections à coronavirus</term>
<term>Lymphocytes T</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term>
<term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Cytokines</term>
<term>Pneumonia, Viral</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Cytokine Release Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cytokine Release Syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunologic Factors</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Facteurs immunologiques</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Lymphocytes T</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term>
<term>Gene Expression Regulation</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Pandémies</term>
<term>Régulation de l'expression des gènes</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32405269</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-7035</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>216</Volume>
<PubDate><Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Clinical immunology (Orlando, Fla.)</Title>
<ISOAbbreviation>Clin Immunol</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>108464</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1521-6616(20)30319-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2020.108464</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Omarjee</LastName>
<ForeName>Loukman</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France. Electronic address: loukman.omarjee@chu-rennes.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Janin</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perrot</LastName>
<ForeName>Frédérique</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Cellular and Molecular Biology Consultant, Rennes F-35033, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Laviolle</LastName>
<ForeName>Bruno</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Meilhac</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mahe</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Immunol</MedlineTA>
<NlmUniqueID>100883537</NlmUniqueID>
<ISSNLinking>1521-6616</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Declaration of Competing Interest All authors declare they have nothing to disclose, and no competing interests.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>05</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32405269</ArticleId>
<ArticleId IdType="doi">10.1016/j.clim.2020.108464</ArticleId>
<ArticleId IdType="pii">S1521-6616(20)30319-3</ArticleId>
<ArticleId IdType="pmc">PMC7217787</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>La Réunion</li>
<li>Région Bretagne</li>
<li>Île-de-France</li>
</region>
</list>
<tree><country name="France"><region name="Région Bretagne"><name sortKey="Omarjee, Loukman" sort="Omarjee, Loukman" uniqKey="Omarjee L" first="Loukman" last="Omarjee">Loukman Omarjee</name>
</region>
<name sortKey="Janin, Anne" sort="Janin, Anne" uniqKey="Janin A" first="Anne" last="Janin">Anne Janin</name>
<name sortKey="Laviolle, Bruno" sort="Laviolle, Bruno" uniqKey="Laviolle B" first="Bruno" last="Laviolle">Bruno Laviolle</name>
<name sortKey="Mahe, Guillaume" sort="Mahe, Guillaume" uniqKey="Mahe G" first="Guillaume" last="Mahe">Guillaume Mahe</name>
<name sortKey="Meilhac, Olivier" sort="Meilhac, Olivier" uniqKey="Meilhac O" first="Olivier" last="Meilhac">Olivier Meilhac</name>
<name sortKey="Perrot, Frederique" sort="Perrot, Frederique" uniqKey="Perrot F" first="Frédérique" last="Perrot">Frédérique Perrot</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000032 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000032 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Bois |area= RapamycinFungusV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32405269 |texte= Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32405269" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a RapamycinFungusV1
This area was generated with Dilib version V0.6.38. |